Skip to main content
Premium Trial:

Request an Annual Quote

Microsoft to Acquire Rosetta Biosoftware from Merck

NEW YORK (GenomeWeb News) – Microsoft has signed an agreement to acquire Rosetta Biosoftware, a unit of Rosetta Inpharmatics, from parent company Merck for undisclosed consideration.

Microsoft said that the deal will enable it to add genetic, genomic, metabolomic, and proteomic data management software into its own Amalga Life Sciences platform for "enhanced translational research capabilities."

Merck will become a customer of the Amalga Life Sciences 2009 platform and provide "strategic input" to Microsoft on the evolution of new solutions that incorporate Rosetta Biosoftware technologies, Microsoft said. The Redmond, Wash.-based software giant launched the Amalga Life Sciences 2009 platform in April.

"The newly combined offering will enable customers to improve the management and analysis of genomic, biological and research data, helping to bring lifesaving drugs and therapies to market faster and accelerate the realization of personalized medicine," Peter Neupert, corporate vice president of the Health Solutions Group at Microsoft, said in a statement.

The firms expect to close the deal at the end of June. Microsoft anticipates the new Amalga platform incorporating the Rosetta Biosoftware technologies to be available early next year. It also said that it is "pursuing hiring Rosetta Biosoftware employees who can fill roles that are critical to the effective incorporation of Rosetta Biosoftware technologies into the Amalga Life Sciences platform."

Until the acquisition is finalized, Rosetta Biosoftware will continue to operate as a unit of Rosetta Inpharmatics.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.